The University of Oxford announced that the coronavirus vaccine trial paused last week will resume.
Due to an illness in one of the volunteers in the vaccine trial, AstraZeneca, the biopharmaceutical company that is developing the vaccine with the University of Oxford, stopped the trial for safety reasons.
The company was testing the vaccine in the UK, the United States, Africa, Latin America, Asia, and Europe before the pause, while the trials will only continue in the UK.
AstraZeneca is trying to work things out with the health authorities from all parts of the world where the vaccine was tested.
The Oxford vaccine was tested on 18,000 people from around the globe, and it is the most successful vaccine so far.
The University came out with a statement, clarifying the situation for the entire population waiting on the vaccine, “In large trials such as this, it is expected that some participants will become unwell and every case must be carefully evaluated to ensure careful assessment of safety.”
AstraZeneca is one of the nine vaccine makers that signed a safety pledge, promising they won’t seek governmental approval for their vaccine unless it is safe for people to take it.